NCT05474885 - BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)

Interventions

BIOLOGICAL

BCMA-CD19 cCAR T cells

BCMA-CD19 cCAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.

Trial Locations (1)

Unknown

RECRUITING

Zhongshan People's Hospital, Zhongshan